Le CNCH au congrès de l ESC 2013
|
|
|
- Piers Allen
- 9 years ago
- Views:
Transcription
1 Le CNCH au congrès de l ESC 2013 Chers amis, chers collègues, Le dynamisme de la recherche clinique dans les centres du CNCH, déjà soulignée dans le livre blanc, s est à nouveau exprimé lors du congrès de la Société Européenne de Cardiologie qui s est tenu à Amsterdam du 31 août au 4 septembre Sur les communications présentées, issues de 87 pays, 382 ont été soumises par des équipes françaises ; parmi elles 37 (10%) ont été le résultat direct de travaux menés par des centres du CNCH ou ont associé des centres du CNCH. Au total, 77 cardiologues et 43 centres du CNCH ont ainsi été représentés (liste par centre et par auteur sur le site du CNCH : Voici le recensement de ces travaux, regroupés selon quatre grands axes de recherche, avec les références vous permettant d accéder au résumé sur le site de l ESC ( Un numéro précédé de la lettre P signale un poster. Cette liste peut comporter des erreurs ou omissions, merci de me les signaler. Bien confraternellement et cordialement. Pour le groupe Recherche Clinique du CNCH Jean-Louis Georges [email protected] 1
2 1. Les études multicentriques promues par le CNCH ou dans le cadre du CNCH : L étude randomisée MIMI, présentée oralement par Loic Belle Deferred stenting in primary percutaneous coronary intervention: the Minimal Intervention for Myocardial Infarction (MIMI) study. L. Belle 1, L. Mangin 1, P. Motreff 2, X. Marcaggi 3, G. Range 4, O. Dubreuil 5, R. Dauphin 6, K. Yayehd 1, J.L. Bosson 7, P. Croisille 8, 1 Hospital of Annecy - Annecy - France, 2 University Hospital of Clermont-Ferrand - Clermont-Ferrand - France, 3 Hospital of Vichy - Vichy - France, 4 Hospital of Chartres - chartres - France, 5 Hospital Center St Joseph - St Luc - Lyon - France, 6 University Hospital of Lyon - Hospital of La Croix Rousse - Lyon - France, 7 University Hospital of Grenoble - Grenoble - France, 8 University Hospital of Saint-Etienne - Saint-Etienne France. L enquête observationnelle RAY ACT, qui a fait l objet de deux posters présentées par Jean-Louis Georges : P1261. Prevalence of high and very high radiation doses to patients during percutaneous coronary interventions. J.L. Georges 1, L. Belle 2, L. Orion 3, S. Elhadad 4, X. Marcaggi 5, F. Funck 6, F. Vinchon 7, C. Maccia 1, B. Livarek 1, S. Cattan 8 1 CH de Versailles - Le Chesnay - France, 2 CH d'annecy and RENAU - Annecy - France, 3 CH de la Roche sur Yon La Roche sur Yon France, 4 CH de Lagny Lagny France, 5 CH de Vichy Vichy France, 6 CH René Dubos - Pontoise France, 7 CH du Mans Le Mans France, 8 CHI Montfermeil Le Raincy France, Collège National des Cardiologues des Hôpitaux - Paris France. P5436. Is radial route associated with higher radiation doses to patient during percutaneous coronary interventions? J.L. Georges 1, M. Hanssen 2, J. Monsegu 3, P. Goube 4, B. Moquet 5, T. Carreres 6, S. Werquin 7, A. Akesbi 8, L. Belle 9, S. Cattan 10 1 CH de Versailles - Le Chesnay - France, 2 CH d Haguenau Haguenau France, 3 HIA Val de Grâce Paris France, 4 CH Sud Francilien Evry-Corbeil France, 5 CH de Saint Brieuc France, 6 CH d Argenteuil Argenteuil France, 7 CH de Dunkerke France, 8 CH d Eaubonne Montmorency Eaubonne 6 France, 9 CH d Annecy Annecy France, 10 CHI Montfermeil Le Raincy France et Collège National des Cardiologues des Hôpitaux - Paris France Le travail de Walid Amara et du groupe de rythmologie, présenté en poster par Karim Gacem du CH de Chollet : P5635. Pacemakers patients perception of daily life activities and follow-up: a French survey. W. Amara 1, S. Cheggour 2, H. Salih 1, A. Elhraiech 1, J. Taieb 3, G. Glerici 1, F. Ghanem 4, A. Dompinier 5, B. Lahitton 6, K. Gacem 1, 1 GHI Le Raincy-Montfermeil - Montfermeil - France, 2 Avignon Hospital Center - Avignon - France, 3 General Hospital of Aix en Provence - Aix en Provence - France, 4 General Hospital - Chateauroux - France, 5 Hospital of Annecy - Annecy - France, 6 Hospital of Dax - Dax France 2. Les études mono ou bicentriques réalisées par les centres du CNCH : Les CH d Antibes et d Avignon : P2055. Prevalence, predictors and outcomes of coronary artery spasm during dobutamine stress echocardiography in patients without known coronary disease. F. Aboukhoudir 1, S. Rekik 2, 1 avignon hospital center - avignon - France, 2 Hospital La Fontonne - Antibes France Le Centre Chirurgical Marie Lannelongue, le Plessis Robinson : P3920. Analysis of residual thrombotic burden after thrombus aspiration in acute myocardial infarction: an optical coherence tomographic evaluation. S. Hammas 1, C. Caussin 1, C. Hurt 1, S. Fradi 1, S. Ghostine 1, N. Amabile 1, 1 Marie Lannelongue Hospital, Department of Cardiology - Le Plessis-Robinson France 2
3 P3949. Intra-coronary thrombus evolution during acute coronary syndrome: regression assessment by serial optical coherence tomography analyses. N. Amabile 1, S. Hammas 1, A. Veugeois 1, C. Caussin 1, 1 Marie Lannelongue Hospital, Department of Cardiology - Le Plessis-Robinson France Microparticles (Communication orale de Nicolas Amabile, expert invité à un symposium ESC intitulé «Emerging markers for cardiovascular prevention») Nicolas AMABILE (Le Plessis Robinson, FR) Le CH de Montreuil : P3952. CathLab procedures change induce great improvements in radiation safety for patients and healthcare professionals. J. Abtan 1, M. Kerneis 1, A. Boccara 1, A. Chaib 1, L. Payot 1, S. Sayah 1, S. Alperin 1, S. Passefort 1, A. Koubbi 1, R. Gryman 1, 1 CHI Andre Gregoire - Montreuil France Le CH de Pontoise et le GHI Le Raincy-Montfermeil P5577. Transient atrioventricular block associated with sickle cell disease : a French survey. P.H. Gacon 1, A. Elhraiech 2, P. Jourdain 3, N. Heba 1, W. Amara 2, 1 University Hospital Center (CHU) Dijon - Dijon - France, 2 GHI Le Raincy-Montfermeil - Montfermeil - France, 3 Rene Dubos Hospital Center, Department of Cardiology - Pontoise France Le CH de Versailles : P4707. Assessment of coronary bypass graft patency by first-line multi-slice computed tomography analysis: a valuable strategy? D. Pesenti-Rossi 1, J.L. Georges 1, N. Baron 1, S. Augusto 1, B. Livarek 1, 1 Hospital - Versailles France Le CH d Annecy (avec le Service de Blida en Algérie) 28. Delayed stenting compared with immediate stenting in patients with STsegment elevation myocardial infarction. M. Chettibi 1, K. Yayehd 2, C. Ricard 2, A. Ghorab 1, M. Bouraghda 1, S. Bertal 1, R. Nedjar 1, M.A. Bouzid 1, M.T. Bouafia 1, L. Belle 2, 1 University Hospital of Frantz Fanon - Blida - Algeria, 2 Hospital of Annecy - Annecy France. 3. Les études menées en partenariat avec un CHU : Collaboration CHU Nice - CH Antibes P1142. Prevalence of patent foramen ovale and stroke in pulmonary embolism patients O. Chiche 1, M. Castellani 2, D. Doyen 1, P. Moceri 1, D. Baudouy 1, R. Saady 1, P. Cerboni 1, E. Ferrari 1, 1 University Hospital of Nice - Hospital Pasteur - Nice - France, 2 Hospital La Fontonne - Antibes France Collaboration CHU Amiens - CH Saint Quentin P1533. Coronary artery disease and mode of death in heart failure with preserved and with reduced ejection fraction - a prospective 10-year study. D. Rusinaru 1, M. Peltier 2, D. Houpe 1, L. Leborgne 2, C. Tribouilloy 2, 1 Centre Hospitalier de Saint Quentin - Saint Quentin - France, 2 Amiens University Hospital - Hospital Sud - Amiens - France Collaboration CHU Rennes - CH Lorient P2984. Very late effects of dual chamber pacing therapy for obstructive, hypertrophic cardiomyopathy. A. Lucon 1, L. Palud 2, D. Pavin 1, E. Donal 1, N. Behar 1, C. Leclercq 1, P. Mabo 1, J.C. Daubert 1, 1 CHU Rennes, University Rennes 1 - Rennes - France, 2 Hospital of Lorient, Department of Cardiology - Lorient - France 3
4 Collaboration AP-HM/CHU Marseille - IMM Paris P490. Significant decrease of pulmonary veins activity by stand-alone atrialsubstrate ablation strategy in persistent atrial fibrillation. J. Seitz 1, C. Bars 2, A. Maluski 1, G. Penaranda 1, J. Faure 1, M. Bremondy 1, A. Ferracci 1, L. Curel 1, A. Pisapia 1, 1 St. Joseph Hospital - Marseille - France, 2 Private Hospital Institute Mutualiste Montsouris - Paris France Collaboration AP-HP/CHU Paris - CH Blois et CH Pontoise P4211. BNP usefulness in very elderly dyspneic patients. The BED Study M. Plichart 1, G. Orvoen 1, P. Jourdain 2, M. Escande 3, P. Friocourt 4, J. Coste 5, L. Quinquis 5, F.X. Chedhomme 1, J.S. Vidal 1, O. Hanon 1, 1 AP-HP - Hospital Broca - Paris - France, 2 Rene Dubos Hospital Center, Department of Cardiology - Pontoise - France, 3 Clinic Vert Coteau - Marseille - France, 4 Hospital - Blois - France, 5 AP-HP - Hospital Hotel-Dieu - Paris France Collaboration CHU Paris, Lyon, Marseille CH Antibes P4846. Clopidogrel pretreatment effect according to the clinical presentation in patients undergoing percutaneous coronary intervention: a meta-analysis. A. Bellemain-Appaix 1, S. O'Connor 2, J. Silvain 2, M. Cucherat 3, F. Beygui 4, O. Barthelemy 2, J.-P. Collet 2, L. Jacq 1, F. Bernasconi 1, G. Montalescot 2, 1 Hospital La Fontonne - Antibes - France, 2 AP-HP - Hospital Pitie-Salpetriere - Paris - France, 3 University Hospital of Lyon - Hospital Louis Pradel - Lyon - France, 4 CHU de Caen, Université Caen Basse-Normandie EA4650, Department of Cardiology - Caen - France Collaboration AP-HP/CHU Paris CCML Le Plessis Robinson Long-term outcomes after heart transplantation in adult patients with cardiac congenital heart disease: impact of initial defect and repair: a collaborative study on 97 patients. S. Cohen 1, L. Houyel 2, R. Guillemain 3, S. Varnous 4, J.L. Golmard 5, L. Iserin 1, 1 AP-HP - European Hospital Georges Pompidou, Department of Cardiology - Paris - France, 2 Surgery Center Marie-Lannelongue - Le Plessis-Robinson - France, 3 AP-HP - European Hospital Georges Pompidou, Department of Cardiac Surgery - Paris - France, 4 AP-HP - Hospital Pitie-Salpetriere, Department of Cardiovascular Surgery - Paris - France, 5 AP-HP - Hospital Pitie-Salpetriere, Department of Biostatistics - Paris - France Collaboration AP-HP-INSERM / HIA Val de Grâce P4854. Reversal of anticoagulant effects of apixaban with non-specific prohaemostatic agents: an in vitro study A.C. Martin 1, B. Le Bonniec 2, C.M. Samama 3, A.M. Fischer 4, A. Godier 3, 1 Military Hospital (HIA) Val de Grace - Paris - France, 2 Inserm U765 - Paris Descartes University - Paris - France, 3 AP-HP - Hospital Cochin, Paris Descartes University - Paris - France, 4 AP-HP - European Hospital Georges Pompidou - Paris - France, 4. Les essais et les registres multicentriques auxquels ont activement participé les centres du CNCH : Essai ARCTIC P4819. Higher on-treatment platelet reactivity and more bleeding complications in the elderly: insight from the ARCTIC study. G. Cayla 1, J.P. Collet 2, C. Pouillot 3, Z. Boueri 4, T. Cuisset 5, S. Elhadad 6, E. Van Belle 7, J. Silvain 2, E. Vicaut 8, G. Montalescot 2, 1 University Hospital of Nimes, Department of Cardiology - Nimes - France, 2 AP-HP - Hospital Pitie- Salpetriere - Paris - France, 3 Clinic Sainte Clothilde - Sainte Clothilde - Reunion, 4 CH Bastia - Bastia - France, 5 AP-HM - Hospital La Timone - Marseille - France, 6 Hospital of Lagny - Marne-la-Vallee - Lagny sur Marne - France, 7 Hospital Regional University of Lille - Cardiological Hospital - Lille - France, 8 Hopital Lariboisiere, Unite de Recherche Clinique - Paris - France P4844. High on-treatment platelet reactivity, a marker of bleeding risk? An analysis of the ARCTIC study. J.-P. Collet 1, G. Cayla 2, L. Belle 3, C. Pouillot 4, Z. Boueri 5, T. Cuisset 6, S. Elhadad 7, J. Silvain 1, E. Vicaut 8, G. Montalescot 1, 1 AP-HP - Hospital Pitie-Salpetriere - Paris - France, 2 CHU Carémeau - Nîmes - France, 3 CH de la Region d'annecy - Annecy - France, 4 Clinic Sainte Clothilde - Sainte Clothilde - Reunion, 5 CH Bastia - Bastia - France, 6 AP-HM - Hospital La Timone - Marseille - France, 7 Hospital of Lagny - Marne-la-Vallee - Lagny sur Marne - France, 8 Hopital Lariboisiere, Unite de Recherche Clinique - Paris France 4
5 P4853. Impact of dual non-responsiveness to aspirin and clopidogrel on clinical outcomes in patients treated with drug-eluting stents in the ARCTIC study. T. Cuisset 1, J. Silvain 2, G. Cayla 3, P. Motreff 4, D. Carrie 5, Z. Boueri 6, E. Van Belle 7, E. Vicaut 8, J.P. Collet 2, G. Montalescot 2, 1 AP-HM - Hospital La Timone - Marseille - France, 2 AP-HP - Hospital Pitie-Salpetriere - Paris - France, 3 University Hospital of Nimes, Department of Cardiology - Nimes - France, 4 University Hospital of Clermont-Ferrand, Department of Cardiology - Clermont-Ferrand - France, 5 University Hospital of Toulouse - Rangueil Hospital, Department of Cardiology - Toulouse - France, 6 Dpt of Cardiology - Bastia - France, 7 Hospital Regional University of Lille - Cardiological Hospital, Department of Cardiology - Lille - France, 8 AP-HP - Hospital Lariboisiere, Clinical Research Unit - Paris - France P4876. Platelet function testing to adjust antiplatelet therapy for elective coronary stenting: a landmark analysis of the ARCTIC trial. G. Montalescot 1, G. Range 2, L. Belle 3, C. Pouillot 4, Z. Boueri 5, G. Cayla 6, E. Van Belle 7, J. Silvain 1, E. Vicaut 8, J.P. Collet 1, 1 AP-HP - Hospital Pitie-Salpetriere - Paris - France, 2 Chartres Hospitals - Hospital Louis Pasteur, Department of Cardiology - Chartres - France, 3 CH de la Region d'annecy - Annecy - France, 4 Clinic Sainte Clothilde - Sainte Clothilde - Reunion, 5 CH Bastia - Bastia - France, 6 CHU Carmeau - Nîmes - France, 7 Hospital Regional University of Lille - Cardiological Hospital - Lille - France, 8 Hopital Lariboisiere, Unite de Recherche Clinique - Paris - France Essai OTELLO P1246. An observational, prospective, non-randomized multicenter study on the use of long TAXUS Element stents in long coronary lesions.primary endpoint report of the OTELLO trial. L. Levai 1, N. Dumonteil 2, V. Stratiev 3, G. Lapeyre 4, C. Caussin 5, P. Ohlmann 6, Z. Boueri 7, R. Levy 8, J. Rischner 1, M.C. Morice 9, 1 Hospital Albert Schweitzer - Colmar - France, 2 University Hospital of Toulouse - Rangueil Hospital - Toulouse - France, 3 CCN- Clinique Cardiologique du Nord - St Denis - France, 4 Hospital Center of Albi - Albi - France, 5 Marie Lannelongue Hospital, Department of Cardiology - Le Plessis-Robinson - France, 6 University Hospital of Strasbourg, Department of Cardiology - Strasbourg - France, 7 Centre Hospitalier - Bastia - France, 8 Clinique St-Martin - Pessac - France, 9 CERC - Massy - France Registre FAST-MI Long-term prognostic impact of body mass index and waist circumference in hospital survivors of acute myocardial infarction. Data from the French FAST- MI 2005 registry N. Danchin 1, E. Puymirat 1, M. Zeller 2, P.G. Steg 3, J. Machecourt 4, N. Delarche 5, P.V. Ennezat 6, F. Schiele 7, J. Ferrieres 8, T. Simon 9, 1 AP-HP - European Hospital Georges Pompidou - Paris - France, 2 University Hospital Center (CHU) Dijon - Dijon - France, 3 AP-HP - Hospital Bichat-Claude Bernard, Department of Cardiology - Paris - France, 4 CHU - Grenoble - France, 5 Hospital Francois Mitterand - Pau - France, 6 Eaux-Claires Clinic - Grenoble - France, 7 University Hospital of Besancon - Hospital Jean Minjoz, Department of Cardiology - Besancon - France, 8 University Hospital of Toulouse - Toulouse - France, 9 AP-HP - Hospital Saint Antoine, Clinical Research Unit (URC) - Est - Paris France Patients discharged with high heart rate after acute myocardial infarction are at increased risk of death over the first year: Five-year follow-up from the FAST-MI 2005 registry M.F. Seronde 1, R. Chopard 1, R. Geha 2, G. Traisnel 3, R. Koning 4, S. Janin 1, N. Meneveau 1, T. Simon 5, N. Danchin 6, F. Schiele 1, 1 University Hospital of Besancon - Besancon - France, 2 CHI Robert Ballanger - Aulnay - France, 3 Policlinic Du Bois - Lille - France, 4 Clinic Saint-Hilaire - Rouen - France, 5 AP-HP - Hospital Saint-Antoine, Faculty of Medicine Pierre & Marie Curie Paris 6 - Paris - France, 6 AP-HP - European Hospital Georges Pompidou, Department of Cardiology - Paris - France P414. Blood transfusion per se does not impact survival in AMI patients. A propensity-score analysis from the French FAST-MI 2005 registry G. Ducrocq 1, E. Puymirat 2, N. Danchin 2, P. Henry 3, M. Martelet 4, P.V. Ennezat 5, F. Schiele 6, P.G. Steg 1, J. Ferrieres 7, T. Simon 8, 1 AP-HP - Hospital Bichat-Claude Bernard, Department of Cardiology - Paris - France, 2 AP-HP - European Hospital Georges Pompidou - Paris - France, 3 AP-HP - Hospital Lariboisiere, Department of Cardiology - Paris - France, 4 General Hospital Langres - Langres - France, 5 Eaux-Claires Clinic - Grenoble - France, 6 University Hospital of Besancon - Besancon - France, 7 University Hospital of Toulouse - Toulouse - France, 8 AP-HP - Hospital Saint Antoine - Paris France 5
6 P922. Renal insufficiency impacts on early and late mortality after acute coronary syndrome after adjustment for comorbidities and management. Insights from the FAST MI 2005 registry N. Meneveau 1, E. Puymirat 2, S. Allam 3, R.G. Huguet 4, F. Schiele 1, J. Ferrieres 5, T. Simon 6, N. Danchin 2, 1 University Hospital of Besancon - Hospital Jean Minjoz - Besancon - France, 2 AP-HP - European Hospital Georges Pompidou, Department of Cardiology - Paris - France, 3 Centre Hospitalier - Verdun - France, 4 Clinic La Reine Blanche - Orleans - France, 5 University Hospital of Toulouse - Rangueil Hospital - Toulouse - France, 6 AP-HP - Hospital Saint- Antoine, Faculty of Medicine Pierre & Marie Curie Paris 6 - Paris France P1303. Preponderant role of reduced early mortality in the reduction of one-year mortality in STEMI from 1995 to 2010: data from 4 French nationwide surveys over 15 years E. Puymirat 1, N. Danchin 1, P.G. Steg 2, D. Blanchard 3, P. Gueret 4, S. Cattan 5, J.P. Cambou 6, J. Ferrieres 6, T. Simon 7, 1 AP-HP - European Hospital Georges Pompidou - Paris - France, 2 AP-HP - Hospital Bichat-Claude Bernard, Department of Cardiology - Paris - France, 3 Clinic Saint Gatien - Tours - France, 4 AP-HP - University Hospital Henri Mondor - Creteil - France, 5 GHI Le Raincy-Montfermeil - Montfermeil - France, 6 University Hospital of Toulouse - Toulouse - France, 7 AP- HP - Hospital Saint Antoine, Clinical Research Unit (URC) - Est - Paris France P1319. In-hospital outcomes and long-term mortality according to gender and management strategy in acute myocardial infarction. Insights from the FAST-MI 2005 Registry T. Simon 1, M. Donataccio 2, E. Puymirat 2, G. Steg 3, H. Eltchaninoff 4, S. Charpentier 5, S. Weber 6, D. Vilarem 7, J. Ferrieres 8, N. Danchin 2, 1 AP-HP - Hospital Saint-Antoine, Faculty of Medicine Pierre & Marie Curie Paris 6 - Paris - France, 2 AP-HP - European Hospital Georges Pompidou - Paris - France, 3 AP-HP - Hospital Bichat-Claude Bernard - Paris - France, 4 Hopital Charles Nicolle, Department of Cardiology - Rouen - France, 5 Purpan University Hospital, Emergency Department, - Toulouse - France, 6 AP-HP - Hospital Cochin, Department of Cardiology - Paris - France, 7 Valenciennes General Hospital, Department of Cardiology - Valenciennes - France, 8 Inserm UMR 1027, University of Toulouse - Toulouse France P3112. Impact of chronic obstructive pulmonary disease on early and late mortality in patients after an acute myocardial infarction. Insights from FAST- MI 2005 registry F. Schiele 1, E. Puymirat 2, S. Cattan 3, F.X. Soto 4, P. Henry 5, B. Livarek 6, D. Blanchard 7, J. Ferrieres 8, T. Simon 9, N. Danchin 2, 1 University Hospital of Besancon - Besancon - France, 2 AP-HP - European Hospital Georges Pompidou, Department of Cardiology - Paris - France, 3 GHI Le Raincy-Montfermeil - Montfermeil - France, 4 Centre Hospitalier - Auxerre - France, 5 AP-HP - Hospital Lariboisiere - Paris - France, 6 Centre Hospitalier - Versailles - France, 7 Clinic Saint Gatien - Tours - France, 8 University Hospital of Toulouse - Rangueil Hospital - Toulouse - France, 9 AP-HP - Hospital Saint-Antoine, Faculty of Medicine Pierre & Marie Curie Paris 6 - Paris France P3643. Cardiac rehabilitation and five-year mortality after an acute coronary syndrome: the 2005 French FAST-MI registry M. Pouche 1, J.B. Ruidavets 2, M.C. Iliou 3, H. Douard 4, L. Lorgis 5, P. Brunel 6, E.H. Saadouni 7, T. Simon 8, J. Ferrieres 9, N. Danchin 10, 1 University Hospital of Toulouse - Rangueil Hospital, Department of Cardiology - Toulouse - France, 2 University Hospital of Toulouse, Department of Epidemiology, Inserm UMR Toulouse - France, 3 Service de Réadaptation Cardiaque, Hopital Corentin Celton (AP-HP) - Issy les Moulineaux - France, 4 University Hospital of Bordeaux - Hospital Haut Leveque, Departement of Cardiology - Bordeaux-Pessac - France, 5 Service de Cardiologie, University Hospital of Dijon (CHU), Hopital Du Bocage - Dijon - France, 6 Unité; de Soins et de Cardiologie Interventionnelle, Nouvelles Cliniques Nantaises - Nantes - France, 7 Department of Cardiology and Vascular Medicine, Saint-Omer Regional Hospital - Helfaut - France, 8 Department of Pharmacology, AP-HP, Hospital Saint-Antoine - Paris - France, 9 University Hospital of Toulouse - Rangueil Hospital, Department of Cardiology B - Toulouse - France, 10 AP-HP - European Hospital Georges Pompidou, Department of Cardiology - Paris France P4299. Prevalence, clinical profile and 3-year outcomes of acute myocardial infarction patients with and without obstructive coronary lesions: the FAST-MI 2005 registry R. Andre 1, M. Elbaz 2, T. Simon 3, E. Puymirat 4, P.V. Ennezat 5, P. Ohlmann 6, V. Probst 7, B. Peltier 8, J. Ferrieres 2, N. Danchin 4, 1 University Hospital of Toulouse - Rangueil Hospital, Department of Cardiology - Toulouse - France, 2 University Hospital of Toulouse - Rangueil Hospital, Department of Cardiology B - Toulouse - France, 3 Department of Pharmacology, Hospital Saint Antoine (AP-HP) - Paris - France, 4 AP-HP - European Hospital Georges Pompidou, Department of Cardiology - Paris - France, 5 Department of Cardiology, Eaux-Claires Clinic - Grenoble - France, 6 Department of cardiovascular surgery, Strasbourg University Hospital, Civil Hospital - Strasbourg - France, 7 Department of Cardiology, University Hospital of Nantes - Nantes - France, 8 Department of Cardiology, Regional 6
7 Hospital of Ploermel - Ploërmel - France Registre ORBI (observatoire Régional Breton des Infarctus) : P2237. Gender differences in presentation, management and intra hospital outcome in patients with ST-elevation myocardial infarction. Data from 5000 patients in ORBI, a prospective French registry. G. Leurent 1, V. Auffret 1, J.P. Hacot 2, B. Moquet 3, P. Druelles 4, E. Filippi 5, G. Rouault 6, A. Rialan 7, P. Castellant 8, H. Le Breton 1, 1 Département de Cardiologie et Maladies Vasculaires, CHU - Rennes - France, 2 Hospital of Lorient, Department of Cardiology - Lorient - France, 3 Service de Cardiologie - Saint Brieuc - France, 4 Polyclinic Saint Laurent - Rennes - France, 5 Hospital of Vannes, Department of Cardiology - Vannes - France, 6 Hospital of Quimper, Department of Cardiology - Quimper - France, 7 Hospital of Saint Malo, Department of Cardiology - Saint Malo - France, 8 University Hospital of Brest, Department of Cardiology - Brest - France Registre RICO (registre des infarctus de la Côte d Or) : P4826. Impact of admission hyperglycemia on one-year mortality in non-diabetic patients admitted for rescue PCI. A. Gudjoncik 1, L. Lorgis 1, J. Ravisy 2, P. Buffet 1, P. Brunel 2, L. Janin-Manificat 3, J.C. Beer 1, D. Brunet 2, M. Zeller 4, Y. Cottin 1, 1 University Hospital Center, Department of Cardiology - Dijon - France, 2 Clinic, Department of Cardiology - Fontaine les Dijon - France, 3 Hospital Center of Beaune, Department of Cardiology - Beaune - France, 4 University of Burgundy, LPPCM, UMR INSERM U866 - Dijon - France Registre CARDIO-ARSIF (cardiologie interventionnelle, ARS Ile de France) P1271. Primary angioplasty in Nonagenarians. G. Helft 1, J.L. Georges 2, C. Caussin 3, H. Benamer 1, O. Varenne 4, E. Teiger 5, Y. Lambert 2, B. Livarek 2, X. Mouranche 6, S. Bataille 6, 1 Institut de Cardiologie - Paris - France, 2 HOPITAL - VERSAILLES - France, 3 CMC - LE PLESSIS ROBINSON - France, 4 AP-HP - Hospital Cochin, Department of Cardiology - Paris - France, 5 AP-HP - University Hospital Henri Mondor, Department of Cardiology - Creteil - France, 6 AP-HP - Hospital Saint-Antoine, Faculty of Medicine Pierre & Marie Curie Paris 6 - Paris - France 7
ARCTIC investigators s
ARCTIC investigators s ARCTIC: Assessment by a double Randomization of a Conventional antiplatelet strategy versus a monitoring-guided strategy for drug-eluting stent implantation and, of Treatment Interruption
RESEARCH TAX CREDIT. Innovation. Research and development. A comprehensive offering tailored to all your R&D projects.
taxation of R&D RESEARCH TAX CREDIT A comprehensive offering tailored to all your R&D projects Innovation Research and development Tax leveraging Intellectual property Essential ressources serving your
B. Chevalier, G. Montalescot, J.S. Hulot, L. Belle, G. Cayla on behalf of GIANT Study investigators
CYP2C19 genetic profiling for thienopyridine management after primary percutaneous coronary intervention: Results of the GIANT study NCT01134380 Sponsor: Biotronik B. Chevalier, G. Montalescot, J.S. Hulot,
Supplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Montalescot G, Zeymer U, Silvain J, et
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
Is There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie
«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie I-Reivac Pr Odile Launay Inserm, Université Paris Descartes, AP-HP, Hôpital Cochin, Paris F-CRIN, une infrastructure pour l
The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
HOTEL PARTICULIER EUROSITES
HOTEL PARTICULIER EUROSITES Presentations CONVENTIONS Annual meetings Workshops Product launches Cocktail parties Receptions TRAININGS L HÔTEL PARTICULIER EUROSITES 7, rue de Liège - 75009 Paris T. : +33
Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
Cilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
Rivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment
PLATFORM PARTNERS PARTNERS FOR INTERNATIONAL CLINICAL RESEARCHS
PLATFORM PARTNERS PARTNERS FOR INTERNATIONAL CLINICAL RESEARCHS Coordonnateurs : Pr Corinne Alberti Pr Éric Vicaut 1 WHO ARE WE? Units of Clinical Research APHP Inserm Partner 2 : Lariboisière Partner
Triple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon
Triple thérapie anti-thrombotique chez le coronarien Y Cottin Dijon «Dans la vie, rien n est à craindre, tout est à comprendre» Marie Curie Epidémiologie Aspirine/Clopidogrel/Ticagrelor/Prasugrel Durée?
New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
DATE: 29 August 2012 CONTEXT AND POLICY ISSUES
TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012 CONTEXT AND POLICY
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
The French Approach to Rapid Transit Mode Selection and Project Planning Thierry Gouin / Certu
The French Approach to Rapid Transit Mode Selection and Project Planning Thierry Gouin / Certu Transport Forum / World Bank / Washington / 28 March 2006 The Center for the Study of Urban Planning, Transportation
East Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
DIRECTION DE LA SECURITE CIVILE
DIRECTION DE LA SECURITE CIVILE CIVIL PROTECTION MINISTERE DE L INTERIEURL DE L OUTREL OUTRE-MER ET DES COLLECTIVITES TERRITORIALES 1 COGIC POSITION Civil Protection Director Cabinet office Int. relationships
Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
California Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
NON-INVASIVE VENTILATION FOR IMMUNOCOMPROMISED PATIENTS WITH ACUTE RESPIRATORY FAILURE I-VNICTUS STUDY
NON-INVASIVE VENTILATION FOR IMMUNOCOMPROMISED PATIENTS WITH ACUTE RESPIRATORY FAILURE I-VNICTUS STUDY Groupe de Recherche en Réanimation Respiratoire du patient d'onco- Hématologie (GRRR-OH) V Lemiale
CMR and MDCT in Cardiac Masses
CMR and MDCT in Cardiac Masses Alexis Jacquier CMR and MDCT in Cardiac Masses Author Alexis Jacquier, M.D., Ph.D. Service d imagerie Médicale Adulte CHU la Timone 264 rue Saint-Pierre 13385 Marseille,
University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
FY2015 Final Hospital Inpatient Rule Summary
FY2015 Final Hospital Inpatient Rule Summary Interventional Cardiology (IC) Peripheral Interventions (PI) Rhythm Management (RM) On August 4, 2014, the Centers for Medicare & Medicaid Services (CMS) released
Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012
Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced
Investor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
Automatic External Defibrillators
Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
France NMO GENERAL INFORMATION
France NMO GENERAL INFORMATION NAME AND COUNTRY France ANEMF LANGUAGE English and for some LC French REQUIRED LANGUAGE At least English, sometimes Frence TIME ZONE (GMT+01:00) Brussels, Copenhagen, Madrid,
Michigan Heart & Vascular Institute ON THE ST. JOSEPH MERCY HOSPITAL CAMPUS, ANN ARBOR, MICHIGAN
ON THE ST. JOSEPH MERCY HOSPITAL CAMPUS, ANN ARBOR, MICHIGAN Dear Colleague: Cardiovascular medicine has marked an important milestone in the battle against heart disease. The latest available data indicates
Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
Telephone: 514-878-2691 Email: [email protected]
NICOLE PARENT, RN PHD Telephone: 514-878-2691 Email: [email protected] CAREER PROFILE Nicole Parent, RN, PhD is a Senior Consultant in s Strategy and Performance Consulting Group. She is also a nurse
Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
How To Understand The Role Of The Statutory Audit In France
THE FRENCH STATUTORY AUDIT STATUTORY AUDITORS SERVING THE PUBLIC INTEREST The President s editorial French statutory audit, the Commissariat aux Comptes, which was first created in 1863, has demonstrated
The Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY
BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY American Osteopathic Association and the American College of Osteopathic Internists Specific Requirements For Osteopathic Subspecialty Training In Cardiology
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
CARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
Section des Unités de recherche. Evaluation report. Research unit : Troubles du comportement alimentaire de l adolescent. University Paris 11
Section des Unités de recherche Evaluation report Research unit : Troubles du comportement alimentaire de l adolescent University Paris 11 Mars 2009 Section des Unités de recherche Rapport d'évaluation
A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
Diagnostic and Therapeutic Procedures
Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary
Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
AND SYLLABUS FOR INTERVENTIONAL CARDIOLOGY SUBSPECIALITY TRAINING IN EUROPE
CURRICULUM AND SYLLABUS FOR INTERVENTIONAL CARDIOLOGY SUBSPECIALITY TRAINING IN EUROPE Document prepared by: Carlo Di Mario, FESC Germano Di Sciascio, FESC Jean-Luc Dubois-Rande,FESC Rolf Michels, FESC
Antonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
Anticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
Surgeons Role in Atrial Fibrillation
Atrial Fibrillation Surgeons Role in Atrial Fibrillation Steven J Feldhaus, MD, FACS 2015 Cardiac Symposium September 18, 2015 Stages of Atrial Fibrillation Paroxysmal (Intermittent) Persistent (Continuous)
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology American Osteopathic Association and American College of Osteopathic Internists BOT 07/2006 Rev. BOT 03/2009 Rev. BOT 07/2011
Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
FY2015 Proposed Hospital Inpatient Rule Summary
FY2015 Proposed Hospital Inpatient Rule Summary Cardiac Rhythm Management (CRM) Electrophysiology (EP) Interventional Cardiology (IC) Peripheral Intervention (PI) On April 30, 2014, the Centers for Medicare
Recurrent AF: Choosing the Right Medication.
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department
None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
Stent for Life Initiative How can we improve system delay and patients delay in STEMI
Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration
Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses
Diagnosis Code Crosswalk : to 402.01 Hypertensive heart disease, malignant, with heart failure 402.11 Hypertensive heart disease, benign, with heart failure 402.91 Hypertensive heart disease, unspecified,
rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc.
rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc. 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
Prognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
Heart Center Packages
Heart Center Packages For more information and appointments, Please contact The Heart Center of Excellence at the American Hospital Dubai Tel: +971-4-377-6571 Email: [email protected] www.ahdubai.com
The Cardiac Society of Australia and New Zealand
The Cardiac Society of Australia and New Zealand Guidelines on Support Facilities for Coronary Angiography and Percutaneous Coronary Intervention (PCI) including Guidelines on the Performance of Procedures
Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
Antikoagulation und antithrombotische Therapie bei Herzerkrankungen
Antikoagulation und antithrombotische Therapie bei Herzerkrankungen Christian Sticherling Kardiologie Dimitrios Tsakiris Hämatologie Einsatz der Antikoagulation und antithrombotischen Therapie in der Kardiologie
CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)
CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99) March 2014 2014 MVP Health Care, Inc. CHAPTER 9 CHAPTER SPECIFIC CATEGORY CODE BLOCKS I00-I02 Acute rheumatic fever I05-I09 Chronic rheumatic heart
SECOND CARDIOLOGY JOINT SEMINAR. Rome, April 12-13, 2012. Cardiovascular Center OLV Clinic Aalst Belgium. and
SECOND CARDIOLOGY JOINT SEMINAR Rome, April 12-13, 2012 Cardiovascular Center OLV Clinic Aalst Belgium and Cardiology Faculty of Medicine and Psychology Sapienza University, Rome, Italy Cardiology Sacred
NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3
1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications
EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention
EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent
